Latest Biotechnology News

Page 24 of 33
Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in treating FSGS kidney disease has passed its sixth independent safety review with no concerns, reinforcing the drug’s promising safety profile.
Ada Torres
Ada Torres
22 May 2025
Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.
Ada Torres
Ada Torres
22 May 2025
Zoono Group has inked a five-year exclusive contract with Sharpak and OSY to apply its antimicrobial technology on UK soft fruit packaging, aiming to reduce food waste and boost shelf-life.
Ada Torres
Ada Torres
20 May 2025
Avecho Biotechnology has expanded its pivotal Phase III clinical trial for a CBD insomnia treatment by adding new recruitment sites and partnering with pharmaceutical giant Sandoz to boost patient enrolment and regulatory progress.
Ada Torres
Ada Torres
20 May 2025
Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.
Ada Torres
Ada Torres
20 May 2025
Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.
Ada Torres
Ada Torres
16 May 2025
Genetic Technologies Limited has announced significant leadership changes, appointing Michael Walker as Executive Chairman and Managing Director, alongside new executive and board members.
Ada Torres
Ada Torres
15 May 2025
Genetic Technologies Limited has officially exited external administration following the effectuation of a Deed of Company Arrangement, marking a significant shift in its corporate governance and creditor relations.
Ada Torres
Ada Torres
14 May 2025
Holista Colltech Limited has responded to an ASX price query regarding recent unusual trading activity, confirming no undisclosed material information exists to explain the surge.
Ada Torres
Ada Torres
12 May 2025
Bio-Gene Technology Limited has launched a Share Purchase Plan allowing Australian shareholders to invest up to $15,000 at 2.3 cents per share, matching a recent $2.1 million placement. The offer includes free-attaching options, subject to shareholder approval, to support key product development milestones.
Ada Torres
Ada Torres
12 May 2025
Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.
Ada Torres
Ada Torres
8 May 2025
Memphasys Limited has successfully trialed its RoXsta™ Mega Cell High-Throughput Assay, capable of processing 96 antioxidant tests in under an hour, promising a leap forward in rapid, cost-effective oxidative stress analysis.
Ada Torres
Ada Torres
8 May 2025